TEM8 Marks Neovasculogenic Tumor-Initiating Cells in Triple-Negative Breast Cancer.

Jiahui Xu,Xiaoli Yang,Qiaodan Deng,Cong Yang,Dong Wang,Guojuan Jiang,Xiaohong Yao,Xueyan He,Jiajun Ding,Jiankun Qiang,Juchuanli Tu,Rui Zhang,Qun-Ying Lei,Zhi-min Shao,Xiuwu Bian,Ronggui Hu,Lixing Zhang,Suling Liu
DOI: https://doi.org/10.1038/s41467-021-24703-7
IF: 16.6
2021-01-01
Nature Communications
Abstract:Enhanced neovasculogenesis, especially vasculogenic mimicry (VM), contributes to the development of triple-negative breast cancer (TNBC). Breast tumor-initiating cells (BTICs) are involved in forming VM; however, the specific VM-forming BTIC population and the regulatory mechanisms remain undefined. We find that tumor endothelial marker 8 (TEM8) is abundantly expressed in TNBC and serves as a marker for VM-forming BTICs. Mechanistically, TEM8 increases active RhoC level and induces ROCK1-mediated phosphorylation of SMAD5, in a cascade essential for promoting stemness and VM capacity of breast cancer cells. ASB10, an estrogen receptor ERα trans-activated E3 ligase, ubiquitylates TEM8 for degradation, and its deficiency in TNBC resulted in a high homeostatic level of TEM8. In this work, we identify TEM8 as a functional marker for VM-forming BTICs in TNBC, providing a target for the development of effective therapies against TNBC targeting both BTIC self-renewal and neovasculogenesis simultaneously.
What problem does this paper attempt to address?